November 22, 2019
1 min read
Save

Glaukos completes Avedro acquisition

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Glaukos Corporation has completed acquisition of Avedro, Inc., according to a press release.

Under the terms of the all-stock transaction agreement, which was announced in August, Glaukos gained Avedro’s FDA-approved Photrexa keratoconus therapy.

“Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” Thomas Burns, Glaukos president and CEO, said. “This transaction pairs two highly complementary, hybrid pharma and device organizations, combining Avedro’s novel bioactivated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure.”